|
Bugs vs. Drugs: The Pharmacist’s Challenge Podcast CE Activity 2
|
|
|
Episode 7-9
- The PK/PD Challenge Issue 1
- The PK/PD Challenge Issue 2
- The PK/PD Challenge Issue 3
|
Episode 10-12
- The Pharmacist’s Role Issue 1
- The Pharmacist’s Role Issue 2
- The Pharmacist’s Role Issue 3
|
Program Overviews
In Episodes 7-9, Dr. David Burgess and Dr. David Nicolau discuss how PK/PD can be used to optimize antimicrobial dosing
strategies to achieve successful clinical outcomes and minimize the emergence of resistance.
In Episodes 10-12, Dr. Robert Rapp and Dr. David Nicolau provide an overview of antimicrobial stewardship programs and
discuss the benefits when these programs are implemented in conjunction with a stringent infection control policy.
|
Learning Objectives
- Identify PK/PD parameters of antimicrobial agents that are predictive of successful clinical outcomes
- Identify the dosing strategies that increase the probability of meeting PK/PD targets
- Examine the difficulty in achieving PK/PD targets necessary for preventing resistance emergence in Pseudomonas aeruginosa
- Recognize the pharmacist's role in the antimicrobial stewardship team
- Examine the clinical and economic benefits of implementing an antimicrobial stewardship program
- Recognize the benefits of antimicrobial stewardship programs in reducing collateral damage
|
Accreditation
Center for Independent Healthcare Education (the Center) is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education. The Center designates 1.75 contact
hour(s) (0.175 CEUs) of continuing pharmacy education credit to this activity.
ACPE Universal Program Number: 473-999-08-002-H01-P.
To receive a CE Statement of Credit, review all relevant activity information, listen to all six
audio files, and return a completed CE post-test and evaluation form. Documentation of credit will
be mailed 6-8 weeks after receipt of materials.
|
Release Date: April 29, 2008
Expiration Date: June 2, 2009
Time to complete activity: 1.75 hours
|
Off-label Disclosure Statements
In episodes 7, 8, 10, 11, and 12, Non-FDA approved and investigational use of agents is not discussed.
In episode 9, investigational use of cephalexin for the treatment of skin and soft tissue infections caused by
MRSA is discussed. Please refer to the prescribing information of cephalexin for FDA-approved
indications, contraindications, and warnings.
|
Recommended Readings
For additional references for this activity, please click on “Recommended Readings” in the left panel.
|
Listen, Learn, and Earn
Listen to an episode by clicking on it in the left panel. CE forms for this activity will
be made available for download after the release of all six episodes on June 3, 2008.
|
